COMMUNIQUÉS West-GlobeNewswire

Immunovaccine and UConn Health Extend Collaboration to Support Advancement of Patient-Specific Immunotherapies to the Clinic

07/12/2017 - 13:05

HALIFAX, Nova Scotia, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (“Immunovaccine” or the “Company”) (TSX: IMV ) (OTCQX:IMMVF), a clinical stage immunotherapy and vaccine company, today announced an expansion [...]

ObsEva SA to Participate in BMO Healthcare Conference December 14th 2017

07/12/2017 - 13:01

Geneva, Switzerland and Boston, MA -December 7, 2017 - ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions [...]

Fibrocell Announces Pricing of $10.5 Million Underwritten Public Offering

07/12/2017 - 13:00

EXTON, Pa., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC ), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today [...]

Advanced Accelerator Applications Announces Commencement of Novartis Tender Offer

07/12/2017 - 13:00

SAINT-GENIS-POUILLY, France, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ: AAAP ) (AAA or the Company), a leader in nuclear medicine theragnostics, today announced that a direct and [...]

Akcea to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference

07/12/2017 - 13:00

CAMBRIDGE, Mass., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA ), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious [...]

CRISPR Therapeutics Submits First Clinical Trial Application for a CRISPR Gene-Edited Therapy, CTX001 in β-thalassemia

07/12/2017 - 13:00

ZUG, Switzerland and CAMBRIDGE, Mass., Dec. 07, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP ) today announced the submission of a Clinical Trial Application (CTA) for CTX001 in β-thalassemia. CTX001 is an [...]

Nightstar Therapeutics to Participate in BMO Prescriptions for Success Healthcare Conference

07/12/2017 - 12:30

LEXINGTON, Mass. and LONDON, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ: NITE ), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced [...]

Pluristem to Present Data on PLX-R18 in Treatment of Acute Radiation Syndrome at American Society of Hematology’s Annual Meeting

07/12/2017 - 11:08

Data from Phase II-equivalent study demonstrated improved survival and hematological recovery of non-human primates (NHP) exposed to high levels of radiation PLX-R18 cells are in late-stage development as a treatment [...]

SuperSonic Imagine Installs Six Aixplorer® Ultimate Ultrasound Systems at 'Occitanie-Garonne' Medical Imaging Group

07/12/2017 - 11:00

AIX-EN-PROVENCE, France, Dec. 07, 2017 (GLOBE NEWSWIRE) -- SuperSonic Imagine (Euronext:SSI FR0010526814), a company specialising in medical imaging using ultrasound, announced today that it installed six Aixplorer [...]

Tresiba® reduces hypoglycaemia regardless of blood sugar level

07/12/2017 - 09:46

Abu Dhabi, UAE, 7 December 2017 - People with either type 1 or type 2 diabetes treated with Tresiba ® had fewer episodes of low blood sugar (hypoglycaemia) compared with people on insulin glargine U100 regardless of [...]

Ryzodeg® significantly reduces the risk of low blood sugar in people with type 2 diabetes who fast during Ramadan

07/12/2017 - 09:46

Abu Dhabi, UAE, 7 December 2017 - In people with type 2 diabetes who fast during Ramadan, Ryzodeg ® (insulin degludec/insulin aspart) reduced the overall rate of low blood sugar (hypoglycaemia) including severe [...]

PRICING AND FURTHER DETAILS ON THE OFFERING OF NEW SHARES IN ALK-ABELLÓ A/S

07/12/2017 - 08:01

Copenhagen, 2017-12-07 08:01 CET (GLOBE NEWSWIRE) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, [...]

OSE Immunotherapeutics to Resume Accrual in Phase 3 Clinical Trial of Tedopi® in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment

07/12/2017 - 07:30

Independent Data Monitoring Committee recommends future recruitment focused on patients who have previously failed immune checkpoint inhibitor treatment New strategy adjusts for rapidly-evolving clinical practice with [...]

ABLYNX WILL HOST A WEBCAST TO DISCUSS ADDITIONAL DATA FROM ITS PHASE III HERCULES STUDY OF CAPLACIZUMAB IN ACQUIRED TTP FOLLOWING ASH LATE-BREAKING DATA PRESENTATION

07/12/2017 - 07:01

GHENT, Belgium, 7 December 2017 - Ablynx NV [Euronext Brussels and Nasdaq: ABLX] announced today that the Ablynx management team will host a conference call and webcast to present additional data from the Phase III [...]

Novartis tender offer for Advanced Accelerator Applications commences

07/12/2017 - 07:01

Basel, December 7, 2017 - Novartis AG (NYSE: NVS) ("Novartis") today announced that its direct and indirect subsidiary, Novartis Groupe France S.A., a société anonyme organized under the laws of France ("Purchaser"), [...]

INNATE PHARMA ANNOUNCES ITS FINANCIAL CALENDAR FOR 2018

07/12/2017 - 07:01

Innate Pharma announceS ITS FINANCIAL CALENDAR FOR 2018 Marseille, France, December 7, 2017, 7:00 AM CET Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) today announces its financial calendar for [...]

INNATE PHARMA ANNONCE SON CALENDRIER FINANCIER POUR 2018

07/12/2017 - 07:01

INNATE PHARMA ANNONCE SON CALENDRIER FINANCIER POUR 2018 Marseille, le 7 décembre 2017, 7h00 CET Innate Pharma SA (Euronext Paris : FR0010331421 - IPH) annonce aujourd'hui son calendrier financier pour l'année 2018 : 8 [...]

INNATE PHARMA : NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS AT DECEMBER 4, 2017

07/12/2017 - 07:01

NUMBER OF SHARES AND VOTING RIGHTS OF Innate Pharma AS AT December 4, 2017 Marseille, France, December 7, 2017, 7:00 AM CET Pursuant to the article L. 233-8 II of the French « Code de Commerce » and the article 223-16 [...]

INNATE PHARMA : NOUVEAU NOMBRE D'ACTIONS ET DE DROITS DE VOTE D'INNATE PHARMA AU 4 DECEMBRE 2017

07/12/2017 - 07:01

nouveau NOMBRE D'ACTIONS ET DE DROITS DE VOTE d'InnatE Pharma AU 4 décembre 2017 Marseille, le 7 décembre 2017, 7h00 CET Conformément aux articles L. 233-8 II du Code de Commerce et 223-16 du règlement général de l' [...]